Expected outcomes
What should improve.
- Reduction in hot flashes and sleep disruption
- More stable daily energy and mood variability
- Better symptom targeting through route-specific dosing
SIGNAL // LOADING
Loading page
Protocol Provider review
Perimenopause hormone-stability stack
Symptom-first triage with ferritin, thyroid, and route-aware HRT decisions.
- Duration
- 12-52 weeks
- Phases
- 3
- Updated
- 2026-04-27
Medically reviewed byDr. Priya Rao, MD
OB-GYN, Women's Health Lead - updated April 2026How we review
Best fit
Who this protocol is built for.
We screen eligibility before any prescription enters the conversation. Decline is treated as an outcome, not a failure.
- Women with perimenopause symptoms and fluctuating cycles
- Members evaluating transdermal vs oral hormone routes
- Patients with fatigue where ferritin or thyroid may be co-drivers
Contraindications
Who should avoid this path.
These are hard stops. We route into a different protocol or refer out, rather than working around a contraindication.
- Undifferentiated abnormal bleeding without workup
- Active estrogen-dependent malignancy concerns pending specialist review
- History requiring non-hormonal first-line approach
Execution
Phased protocol timeline.
Each phase has explicit entry criteria, actions, and exit conditions. The plan moves on data and tolerance, not a calendar.
Phase 01
Weeks 0-2
Map symptoms to labs
Separate hormone transition symptoms from thyroid, iron, and metabolic overlap.
- Run cycle-aware panel with ferritin, thyroid, estradiol, progesterone, SHBG
- Screen migraine, thromboembolism history, and blood-pressure profile
- Set symptom severity baseline and sleep impact score
Phase 02
Weeks 3-10
Route and dose selection
Choose transdermal-first route for most candidates and titrate to symptom response.
- Start lowest effective estrogen route and pair progesterone when indicated
- Track vasomotor symptoms, sleep continuity, and mood variability
- Adjust route or dose based on tolerance and risk profile
Phase 03
Weeks 11-24+
Reassess and optimize
Confirm symptom gains and ensure risk markers remain in-range.
- Recheck thyroid and ferritin where baseline was abnormal
- Review blood pressure, migraine frequency, and adverse signals
- Lock maintenance cadence with periodic clinical reassessment
Stack components
What this protocol layers.
Prescription
Provider-selected and state-dependent.
Labs
Coaching
- Sleep Support
- Cycle Symptom Tracking
- Recovery And Stress Planning
Risk picture
What we monitor closely.
- Route-specific side effects and dose sensitivity
- Potential blood-pressure and migraine interactions
- Missed non-hormonal contributors if labs are skipped
Monitoring cadence
How we track progress.
- Symptom score trend every 2-4 weeks during adjustments
- Targeted ferritin/thyroid recheck where baseline was abnormal
- Quarterly maintenance follow-up while on active pathway
Labs and availability
Run this protocol where service is live.
Common questions
Perimenopause hormone-stability stack
protocol questions, answered.
Evidence
What perimenopause hormone-stability stack
is built on.
Trials, regulatory guidance, and peer-reviewed evidence the protocol is anchored against.
Keep reading
Guides and pathways tied to this protocol
- Bioidentical vs Synthetic
Bioidentical vs synthetic HRT: what actually changes clinical risk
The bioidentical vs synthetic debate is often more branding than physiology. Route, dose, and monitoring quality usually drive real risk differences. This...
Read - ALUKARD vs Hims
ALUKARD vs Hims: protocol depth versus speed and simplicity
Both platforms improve access, but they optimize for different outcomes. Hims emphasizes speed and convenience. ALUKARD emphasizes biomarker-first protocol...
Read - Guide
Hormone imbalance: where to start when symptoms overlap
"Hormone imbalance" is the most-searched, least-defined term in wellness. Fatigue, weight gain, mood shifts, and low libido can all trace to estrogen, thyroid,...
Read - Guide
Perimenopause labs: the panel most GPs won't order
Perimenopause starts in the late 30s for some women and stretches a decade. Most GPs run a single TSH and FSH and call it inconclusive - because hormones swing...
Read - Care pathway
Women's Health
Ferritin and thyroid get missed more often than hormones do. We read labs across your cycle, not against a one-size reference range.
Read - Definition
Cardiovascular risk stratification
Cardiovascular risk stratification is a clinical condition, procedure, or behavior method used in preventive and metabolic care planning.
Read
Build your plan
Run this protocol where the data points.
Take the assessment and we’ll route you into labs, a foundational stack, coaching, or provider review based on what you answer.